{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:23:13Z","timestamp":1773994993176,"version":"3.50.1"},"reference-count":109,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adapting drug treatments for patients on hemodialysis with multiple chronic\u00a0pathologies\u00a0is a complex affair. When prescribing a\u00a0medication, the risk\u2013benefit analysis usually\u00a0focuses primarily on the indication of the drug class prescribed. However, the pharmacokinetics of the chosen drug should also be taken into account. The purpose of our review was to identify the drugs to be favored in each therapeutic class, according to their safety and pharmacokinetic profiles, for the most common chronic\u00a0diseases in patients on chronic hemodialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of the literature using Medline and Web of Science databases, targeting studies on the most commonly-prescribed drugs for non-communicable diseases in patients on chronic hemodialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search identified 1224 articles, 95 of which were further analyzed. The main classes of drugs included concern the cardiovascular system (anti-hypertensives, anti-arrhythmics, anti-thrombotics, hypocholesterolemics), the endocrine and metabolic pathways (anti-diabetics, gastric anti-secretory, anticoagulant, thyroid hormones, anti-gout) and psychiatric and neurological disorders (antidepressants, anxiolytics, antipsychotics and anti-epileptics).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We report on\u00a0the most often prescribed drugs for chronic pathologies in patients on chronic hemodialysis. Most of them require adaptation, and in some cases one better alternative stands out among the drug class. More pharmacokinetic data are needed to define the pharmacokinetics in the various dialysis techniques.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01477-9","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:02:43Z","timestamp":1670295763000},"page":"521-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Choosing the right chronic medication for hemodialysis\u00a0patients. A short ABC for the dialysis nephrologist"],"prefix":"10.1093","volume":"36","author":[{"given":"Clarisse","family":"Roux","sequence":"first","affiliation":[{"name":"Service Pharmacie, Hopital Universitaire de Nimes, CHU Car\u00e9meau, N\u00eemes, France 1"},{"name":"Institut Desbrest d\u2019Epidemiologie et Sant\u00e9 publique (IDESP), INSERM, Montpellier, France 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristelle","family":"Verollet","sequence":"additional","affiliation":[{"name":"Service Pharmacie, Hopital Universitaire de Nimes, CHU Car\u00e9meau, N\u00eemes, France 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Prouvot","sequence":"additional","affiliation":[{"name":"Institut Desbrest d\u2019Epidemiologie et Sant\u00e9 publique (IDESP), INSERM, Montpellier, France 2"},{"name":"Service N\u00e9phrologie Dialyse Apherese, Hopital Universitaire de Nimes, CHU Car\u00e9meau, N\u00eemes, France 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Prelipcean","sequence":"additional","affiliation":[{"name":"Service N\u00e9phrologie Dialyse Apherese, Hopital Universitaire de Nimes, CHU Car\u00e9meau, N\u00eemes, France 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Pambrun","sequence":"additional","affiliation":[{"name":"Service N\u00e9phrologie Dialyse Apherese, Hopital Universitaire de Nimes, CHU Car\u00e9meau, N\u00eemes, France 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1415","authenticated-orcid":false,"given":"Olivier","family":"Moranne","sequence":"additional","affiliation":[{"name":"Institut Desbrest d\u2019Epidemiologie et Sant\u00e9 publique (IDESP), INSERM, Montpellier, France 2"},{"name":"Service N\u00e9phrologie Dialyse Apherese, Hopital Universitaire de Nimes, CHU Car\u00e9meau, N\u00eemes, France 3"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"8","key":"2026012110171534600_CR1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","article-title":"Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis","volume":"10","author":"Velenosi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"2026012110171534600_CR2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0272-6386(12)80811-0","article-title":"Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers","volume":"23","author":"Agarwal","year":"1994","journal-title":"Am J Kidney Dis janv"},{"issue":"7","key":"2026012110171534600_CR3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ndt\/4.7.635","article-title":"Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration","volume":"4","author":"De Bock","year":"1989","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2026012110171534600_CR4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000170103","article-title":"Drug clearance by continuous haemodiafiltration. Analysis of sieving coefficients and mass transfer coefficients of diffusion","volume":"11","author":"Vincent","year":"1993","journal-title":"Blood Purif"},{"issue":"12","key":"2026012110171534600_CR5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","article-title":"Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy","volume":"46","author":"Pea","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2026012110171534600_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.ajkd.2019.12.002","article-title":"Multidisciplinary medication therapy management and hospital readmission in patients undergoing maintenance dialysis: a retrospective cohort study","volume":"76","author":"Manley","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2026012110171534600_CR7","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/bcp.13738","article-title":"Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort","volume":"84","author":"Laville","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2026012110171534600_CR8","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.2215\/CJN.01420213","article-title":"Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach","volume":"8","author":"Pai","year":"2013","journal-title":"CJASN"},{"key":"2026012110171534600_CR9"},{"key":"2026012110171534600_CR10"},{"issue":"4","key":"2026012110171534600_CR11","doi-asserted-by":"crossref","first-page":"E245","DOI":"10.3390\/diagnostics10040245","article-title":"Thyroid pathology in end-stage renal disease patients on hemodialysis","volume":"10","author":"Cotoi","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2026012110171534600_CR12"},{"key":"2026012110171534600_CR13"},{"key":"2026012110171534600_CR14"},{"key":"2026012110171534600_CR15"},{"issue":"4","key":"2026012110171534600_CR16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0272-6386(95)90123-X","article-title":"Defective platelet aggregation in uremia is transiently worsened by hemodialysis","volume":"25","author":"Sreedhara","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2026012110171534600_CR17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/ndt\/gfy289","article-title":"Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality","volume":"34","author":"You","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2026012110171534600_CR18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40620-019-00592-4","article-title":"Anticoagulation in CKD and ESRD","volume":"32","author":"Leung","year":"2019","journal-title":"J Nephrol"},{"issue":"3","key":"2026012110171534600_CR19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/europace\/euz358","article-title":"Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association\/European Dialysis and Transplantation Association (ERA\/EDTA) physician-based survey","volume":"22","author":"Potpara","year":"2020","journal-title":"EP Europace"},{"issue":"4","key":"2026012110171534600_CR20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2237","article-title":"Anticoagulation for stroke prevention in patients with atrial fibrillation and end-stage renal disease-first, do no harm","volume":"3","author":"Belley-Cote","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026012110171534600_CR21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5853\/jos.2020.01886","article-title":"Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences","volume":"22","author":"Goel","year":"2020","journal-title":"J Stroke"},{"issue":"5","key":"2026012110171534600_CR22","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.kint.2019.04.033","article-title":"Epilepsy and antiseizure medications increase all-cause mortality in dialysis patients in the United States","volume":"96","author":"Waddy","year":"2019","journal-title":"Kidney Int"},{"key":"2026012110171534600_CR23"},{"issue":"7","key":"2026012110171534600_CR24","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/imj.14163","article-title":"Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study","volume":"49","author":"Yeo","year":"2019","journal-title":"Intern Med J"},{"issue":"3","key":"2026012110171534600_CR25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/sdi.12691","article-title":"Beta blockers in patients with end-stage renal disease-evidence-based recommendations","volume":"31","author":"Weir","year":"2018","journal-title":"Semin Dial"},{"issue":"4","key":"2026012110171534600_CR26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2215\/CJN.07470717","article-title":"\u03b2-Blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial","volume":"13","author":"Tieu","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2026012110171534600_CR27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/sdi.12741","article-title":"Blood pressure control in conventional hemodialysis","volume":"31","author":"Georgianos","year":"2018","journal-title":"Semin Dial"},{"issue":"3","key":"2026012110171534600_CR28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2026012110171534600_CR29","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","article-title":"Safety of low-dose spironolactone administration in chronic haemodialysis patients","volume":"18","author":"Saudan","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2026012110171534600_CR30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0091270005275894","article-title":"Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment","volume":"45","author":"Ravis","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2026012110171534600_CR31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1525-139X.2009.00697.x","article-title":"Antihypertensive agents in hemodialysis patients: a current perspective: antihypertensive agents in hemodialysis patients","volume":"23","author":"Inrig","year":"2010","journal-title":"Seminars Dial"},{"issue":"5","key":"2026012110171534600_CR32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.04330418","article-title":"Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD","volume":"14","author":"Sinha","year":"2019","journal-title":"CJASN"},{"issue":"1","key":"2026012110171534600_CR33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2215\/CJN.05080418","article-title":"Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes","volume":"14","author":"Sibbel","year":"2019","journal-title":"CJASN"},{"issue":"5","key":"2026012110171534600_CR34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-91-5-744","article-title":"Furosemide-induced ototoxicity","volume":"91","author":"Gallagher","year":"1979","journal-title":"Ann Intern Med"},{"key":"2026012110171534600_CR35"},{"issue":"2","key":"2026012110171534600_CR36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2018.05.005","article-title":"Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"94","author":"Wanner","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"2026012110171534600_CR37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1525-139X.2010.00778.x","article-title":"Cardiovascular agents","volume":"23","author":"Walton","year":"2010","journal-title":"Seminars Dial"},{"key":"2026012110171534600_CR38"},{"key":"2026012110171534600_CR39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2016.04.007","article-title":"Atrial fibrillation in chronic kidney disease","volume":"33","author":"Voroneanu","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2026012110171534600_CR40","first-page":"174","article-title":"Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C","volume":"90","author":"Brown","year":"2001","journal-title":"Atheroscler"},{"issue":"2","key":"2026012110171534600_CR41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0755-4982(06)74557-2","article-title":"Prescription des statines en cas d\u2019insuffisance r\u00e9nale: Efficacit\u00e9, tol\u00e9rance et maniement chez le patient insuffisant r\u00e9nal et chez le patient transplant\u00e9 r\u00e9nal","volume":"35","author":"Karie","year":"2006","journal-title":"La Presse M\u00e9dicale"},{"key":"2026012110171534600_CR42","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107459","article-title":"Lipid-modifying therapy in chronic kidney disease: pathophysiological and clinical considerations","volume":"207","author":"Heine","year":"2020","journal-title":"Pharmacol Therapeut"},{"issue":"3","key":"2026012110171534600_CR43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cpdd.650","article-title":"Influence of renal function on evolocumab exposure, pharmacodynamics, and safety","volume":"8","author":"Lee","year":"2019","journal-title":"Clin Pharmacol Drug Develop"},{"issue":"1","key":"2026012110171534600_CR44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000182614","article-title":"Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure","volume":"31","author":"Desager","year":"1982","journal-title":"Nephron"},{"issue":"5","key":"2026012110171534600_CR45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/cer-2016-0076","article-title":"Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis","volume":"6","author":"Abdel Magid","year":"2017","journal-title":"J Comp Eff Res"},{"issue":"12","key":"2026012110171534600_CR46","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/j.1552-4604.1987.tb05603.x","article-title":"The effect of renal function on the pharmacokinetics of gemfibrozil","volume":"27","author":"Evans","year":"1987","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2026012110171534600_CR47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00627922","article-title":"Clinical pharmacokinetics of bezafibrate in patients with impaired renal function","volume":"21","author":"Anderson","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2026012110171534600_CR48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1159\/000190235","article-title":"Blood monitoring of bezafibrate in a chronic hemodialysis patient","volume":"76","author":"Takeda","year":"1997","journal-title":"Nephron"},{"issue":"19","key":"2026012110171534600_CR49","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/BF01728614","article-title":"Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects","volume":"64","author":"Gr\u00fctzmacher","year":"1986","journal-title":"Klin Wochenschr"},{"issue":"1","key":"2026012110171534600_CR50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jorc.12266","article-title":"Managing care for people with diabetes undergoing dialysis: managing care for people with diabetes undergoing dialysis","volume":"45","author":"Gregory","year":"2019","journal-title":"J Renal Care"},{"key":"2026012110171534600_CR51","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/j.dsx.2017.03.005","article-title":"The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents","volume":"11","author":"Di Lullo","year":"2017","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"2026012110171534600_CR52","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ndt\/gfz040","article-title":"Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update","volume":"34","author":"Burlacu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2026012110171534600_CR53","first-page":"7","article-title":"Pharmacokinetics of repaglinide in subjects with renal impairment","volume":"67","author":"Marbury","year":"2000","journal-title":"Clin PharmacolTherapeut"},{"issue":"2","key":"2026012110171534600_CR54","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13181-019-00755-6","article-title":"Do Patients Die with or from Metformin-Associated Lactic Acidosis (MALA)? Systematic review and meta-analysis of pH and lactate as predictors of mortality in MALA","volume":"16","author":"Blumenberg","year":"2020","journal-title":"J Med Toxicol"},{"key":"2026012110171534600_CR55"},{"issue":"9","key":"2026012110171534600_CR56","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/00912709922008542","article-title":"Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure","volume":"39","author":"Keane","year":"1999","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2026012110171534600_CR57","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/ndt\/13.5.1189","article-title":"Pharmacokinetics of pantoprazole in patients with end-stage renal failure","volume":"13","author":"Kliem","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2026012110171534600_CR58","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/j.1552-4604.1995.tb04125.x","article-title":"Pharmacokinetics of lansoprazole in hemodialysis patients","volume":"35","author":"Karol","year":"1995","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2026012110171534600_CR59","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/BF00607907","article-title":"Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure","volume":"28","author":"Howden","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2026012110171534600_CR60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10157-015-1130-2","article-title":"Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis","volume":"20","author":"Namikoshi","year":"2016","journal-title":"Clin Exp Nephrol"},{"issue":"687","key":"2026012110171534600_CR61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/pgmj.59.687.25","article-title":"Plasma ranitidine concentrations after intravenous administration in normal volunteers and haemodialysis patients","volume":"59","author":"Roberts","year":"1983","journal-title":"Postgraduate Med J"},{"issue":"1","key":"2026012110171534600_CR62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000185576","article-title":"Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis","volume":"52","author":"Comstock","year":"1989","journal-title":"Nephron"},{"issue":"12","key":"2026012110171534600_CR63","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/j.1552-4604.1988.tb05718.x","article-title":"Ranitidine accumulation in patients undergoing chronic hemodialysis","volume":"28","author":"Comstock","year":"1988","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2026012110171534600_CR64","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0272-6386(84)80006-2","article-title":"Rebound following hemodialysis of cimetidine and its metabolites","volume":"3","author":"Ziemniak","year":"1984","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2026012110171534600_CR65","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2125.1980.tb01084.x","article-title":"Elimination of oral cimetidine in chronic renal failure and during haemodialysis","volume":"9","author":"Bjaeldager","year":"1980","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2026012110171534600_CR66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003088-199324040-00005","article-title":"Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency","volume":"24","author":"Gladziwa","year":"1993","journal-title":"Clin Pharmacokinetics"},{"issue":"3","key":"2026012110171534600_CR67","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000360011","article-title":"Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors","volume":"39","author":"Alhosaini","year":"2014","journal-title":"Am J Nephrol"},{"key":"2026012110171534600_CR68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejim.2016.01.026","article-title":"Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?","volume":"30","author":"Mikolasevic","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"5","key":"2026012110171534600_CR69","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1440-1797.2012.01604.x","article-title":"Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients: effect of acid suppression on calcium carbonate","volume":"17","author":"Cervelli","year":"2012","journal-title":"Nephrology"},{"issue":"08","key":"2026012110171534600_CR70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5414\/CNP68093","article-title":"Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy","volume":"68","author":"Matsunaga","year":"2007","journal-title":"CN"},{"issue":"6","key":"2026012110171534600_CR71","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MNH.0000000000000542","article-title":"Thyroid disease in end-stage renal disease","volume":"28","author":"Rhee","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"2026012110171534600_CR72","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1210\/jc.2016-3616","article-title":"Thyroid status and mortality in a prospective hemodialysis cohort","volume":"102","author":"Rhee","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012110171534600_CR73","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.kint.2019.11.027","article-title":"Role of direct oral anticoagulants in patients with kidney disease","volume":"97","author":"Derebail","year":"2020","journal-title":"Kidney Int"},{"key":"2026012110171534600_CR74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2016.09.016","article-title":"Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"184","author":"Van Der Meersch","year":"2017","journal-title":"Am Heart J"},{"issue":"4","key":"2026012110171534600_CR75","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"JASN"},{"issue":"4","key":"2026012110171534600_CR76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hdi.12571","article-title":"Antithrombotic therapy in end-stage renal disease: antithrombotic therapy in ESRD","volume":"21","author":"Chunduri","year":"2017","journal-title":"Hemodial Int"},{"issue":"9","key":"2026012110171534600_CR77","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022690","article-title":"Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study","volume":"8","author":"Reinecke","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"2026012110171534600_CR78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/gfy031","article-title":"A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation","volume":"34","author":"Feldberg","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2026012110171534600_CR79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00216-010-4220-8","article-title":"Protamine neutralisation of low molecular weight heparins and their oligosaccharide components","volume":"399","author":"Schroeder","year":"2011","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"2026012110171534600_CR80","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40620-016-0367-5","article-title":"Antiplatelet agents in hemodialysis","volume":"30","author":"Migliori","year":"2017","journal-title":"J Nephrol"},{"key":"2026012110171534600_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.02.011","article-title":"Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis","volume":"298","author":"K\u00f6nigsbr\u00fcgge","year":"2020","journal-title":"Atherosclerosis"},{"issue":"2","key":"2026012110171534600_CR82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/138920021602150713114437","article-title":"Evidence-based choice of P2Y12 inhibitors in end stage renal disease patients: a mini-review","volume":"16","author":"Bouatou","year":"2015","journal-title":"CDM"},{"issue":"15","key":"2026012110171534600_CR83","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y 12 -ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes: review of the current evidence","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation"},{"key":"2026012110171534600_CR84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.seizure.2020.02.006","article-title":"Managing the patient with epilepsy and renal impairment","volume":"76","author":"Mahmoud","year":"2020","journal-title":"Seizure"},{"issue":"11","key":"2026012110171534600_CR85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11940-018-0530-5","article-title":"Managing antiepileptic medication in dialysis patients","volume":"20","author":"Mora Rodr\u00edguez","year":"2018","journal-title":"Curr Treat Options Neurol"},{"issue":"7","key":"2026012110171534600_CR86","first-page":"705","article-title":"End-stage renal disease: symptom management and advance care planning","volume":"85","author":"O\u2019Connor","year":"2012","journal-title":"Am Fam Physician"},{"issue":"5","key":"2026012110171534600_CR87","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpainsymman.2004.02.021","article-title":"Opioids in renal failure and dialysis patients","volume":"28","author":"Dean","year":"2004","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"2026012110171534600_CR88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpain.2004.11.009","article-title":"Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted","volume":"6","author":"Launay-Vacher","year":"2005","journal-title":"J Pain"},{"issue":"3","key":"2026012110171534600_CR89","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/hdi.12622","article-title":"Management of pain in end-stage renal disease patients: short review","volume":"22","author":"Raina","year":"2018","journal-title":"Hemodial Int"},{"issue":"5","key":"2026012110171534600_CR90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1590\/1516-4446-2018-0264","article-title":"Pharmacokinetics of antidepressants in patients undergoing hemodialysis: a narrative literature review","volume":"41","author":"Constantino","year":"2019","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"2026012110171534600_CR91","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/0004867414528589","article-title":"Depression and chronic kidney disease: a review for clinicians","volume":"48","author":"Bautovich","year":"2014","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"2026012110171534600_CR92","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/sdi.12370","article-title":"Psychotherapeutic agents in end-stage renal disease","volume":"28","author":"Eyler","year":"2015","journal-title":"Semin Dial"},{"issue":"1","key":"2026012110171534600_CR93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hdi.12540","article-title":"Sertraline can reduce uremic pruritus in hemodialysis patient: a double blind randomized clinical trial from Southern Iran: sertraline and uremic pruritus","volume":"22","author":"Pakfetrat","year":"2018","journal-title":"Hemodial Int"},{"issue":"4","key":"2026012110171534600_CR94","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12325-009-0021-x","article-title":"Psychotropic drugs and renal failure: translating the evidence for clinical practice","volume":"26","author":"Baghdady","year":"2009","journal-title":"Adv Ther"},{"key":"2026012110171534600_CR95"},{"issue":"1","key":"2026012110171534600_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1472-8206.1993.tb00212.x","article-title":"Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients","volume":"7","author":"Fillastre","year":"1993","journal-title":"Fundam Clin Pharmacol"},{"issue":"Suppl 1","key":"2026012110171534600_CR97","first-page":"22","article-title":"Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal subjects. Effect of hemodialysis","volume":"10","author":"Marc-Aurele","year":"1987","journal-title":"Sleep"},{"key":"2026012110171534600_CR98"},{"issue":"1","key":"2026012110171534600_CR99","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/appi.psy.45.1.34","article-title":"Update on psychotropic medication use in renal disease","volume":"45","author":"Cohen","year":"2004","journal-title":"Psychosomatics"},{"issue":"1","key":"2026012110171534600_CR100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046050","article-title":"Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study","volume":"89","author":"Noiri","year":"2001","journal-title":"Nephron"},{"issue":"4","key":"2026012110171534600_CR101","first-page":"316","article-title":"Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial","volume":"9","author":"Nakhaee","year":"2015","journal-title":"Iran J Kidney Dis"},{"issue":"3","key":"2026012110171534600_CR102","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026012110171534600_CR103"},{"key":"2026012110171534600_CR104"},{"issue":"1","key":"2026012110171534600_CR105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/imj.12291","article-title":"Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?: Consistency in renal drug dosing guidelines","volume":"44","author":"Khanal","year":"2014","journal-title":"Intern Med J"},{"issue":"4","key":"2026012110171534600_CR106","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.semnephrol.2018.05.003","article-title":"Precision medicine in the transition to dialysis and personalized renal replacement therapy","volume":"38","author":"Rhee","year":"2018","journal-title":"Seminars Nephrol"},{"issue":"1","key":"2026012110171534600_CR107","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13643-021-01752-z","article-title":"Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis","volume":"10","author":"Okpechi","year":"2021","journal-title":"Syst Rev"},{"issue":"Suppl 2","key":"2026012110171534600_CR108","doi-asserted-by":"crossref","first-page":"ii91","DOI":"10.1093\/ndt\/gfw357","article-title":"Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease","volume":"32","author":"Kalantar-Zadeh","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026012110171534600_CR109"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01477-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/2\/521\/66514302\/joneph_36_2_1477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/2\/521\/66514302\/joneph_36_2_1477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:17:38Z","timestamp":1769008658000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/2\/521\/8303762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":109,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,6]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01477-9","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"17 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"\u00a0No ethical approval was required for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}